Two nurses standing near Mayinga N'Seka, a nurse with Ebola virus disease in the 1976 outbreak in Zaire. N'Seka died a few days later. The nurses are not wearing proper protective equipment.
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses.[1] Symptoms typically start anywhere between two days and three weeks after infection.[3] The first symptoms are usually fever, sore throat, muscle pain, and headaches.[1] These are usually followed by vomiting, diarrhoea, rash and decreased liver and kidney function,[1] at which point some people begin to bleed both internally and externally.[1] It kills between 25% and 90% of those infected – about 50% on average.[1] Death is often due to shock from fluid loss, and typically occurs between six and 16 days after the first symptoms appear.[2] Early treatment of symptoms increases the survival rate considerably compared to late start.[4] An Ebola vaccine was approved by the US FDA in December 2019.
The virus spreads through direct contact with body fluids, such as blood from infected humans or other animals,[1] or from contact with items that have recently been contaminated with infected body fluids.[1] There have been no documented cases, either in nature or under laboratory conditions, of spread through the air between humans or other primates.[5] After recovering from Ebola, semen or breast milk may continue to carry the virus for anywhere between several weeks to several months.[1][6][7]Fruit bats are believed to be the normal carrier in nature; they are able to spread the virus without being affected by it.[1] The symptoms of Ebola may resemble those of several other diseases, including malaria, cholera, typhoid fever, meningitis and other viral hemorrhagic fevers.[1] Diagnosis is confirmed by testing blood samples for the presence of viral RNA, viral antibodies or the virus itself.[1][8]
Control of outbreaks requires coordinated medical services and community engagement,[1] including rapid detection, contact tracing of those exposed, quick access to laboratory services, care for those infected, and proper disposal of the dead through cremation or burial.[1][9] Prevention measures involve wearing proper protective clothing and washing hands when in close proximity to patients and while handling potentially infected bushmeat, as well as thoroughly cooking bushmeat.[1] An Ebola vaccine was approved by the US FDA in December 2019.[10] While there is no approved treatment for Ebola as of 2019[update],[11] two treatments (atoltivimab/maftivimab/odesivimab and ansuvimab) are associated with improved outcomes.[12] Supportive efforts also improve outcomes.[1] These include oral rehydration therapy (drinking slightly sweetened and salty water) or giving intravenous fluids, and treating symptoms.[1] In October 2020, atoltivimab/maftivimab/odesivimab (Inmazeb) was approved for medical use in the United States to treat the disease caused by Zaire ebolavirus.[13]
The length of time between exposure to the virus and the development of symptoms (incubation period) is between 2 and 21 days,[1][24] and usually between 4 and 10 days.[25] However, recent estimates based on mathematical models predict that around 5% of cases may take longer than 21 days to develop.[26]
Recovery may begin between seven and 14days after first symptoms.[28] Death, if it occurs, follows typically six to sixteen days from first symptoms and is often due to shock from fluid loss.[2] In general, bleeding often indicates a worse outcome, and blood loss may result in death.[27] People are often in a coma near the end of life.[28]
Those who survive often have ongoing muscular and joint pain, liver inflammation, and decreased hearing, and may have continued tiredness, continued weakness, decreased appetite, and difficulty returning to pre-illness weight.[28][40] Problems with vision may develop.[41] It is recommended that survivors of EVD wear condoms for at least twelve months after initial infection or until the semen of a male survivor tests negative for Ebola virus on two separate occasions.[42]
Survivors develop antibodies against Ebola that last at least 10 years, but it is unclear whether they are immune to additional infections.[43]
Cause
EVD in humans is caused by four of six viruses of the genus Ebolavirus. The four are Bundibugyo virus (BDBV), Sudan virus (SUDV), Taï Forest virus (TAFV) and one simply called Ebola virus (EBOV, formerly Zaire Ebola virus).[44] EBOV, species Zaire ebolavirus, is the most dangerous of the known EVD-causing viruses, and is responsible for the largest number of outbreaks.[45] The fifth and sixth viruses, Reston virus (RESTV) and Bombali virus (BOMV),[46] are not thought to cause disease in humans, but have caused disease in other primates.[47][48] All six viruses are closely related to marburgviruses.[44]
Ebolaviruses contain single-stranded, non-infectious RNAgenomes.[49]Ebolavirus genomes contain seven genes including 3'-UTR-NP-VP35-VP40-GP-VP30-VP24-L-5'-UTR.[35][50] The genomes of the five different ebolaviruses (BDBV, EBOV, RESTV, SUDV and TAFV) differ in sequence and the number and location of gene overlaps. As with all filoviruses, ebolavirus virions are filamentous particles that may appear in the shape of a shepherd's crook, of a "U" or of a "6," and they may be coiled, toroid or branched.[50][51] In general, ebolavirions are 80 nanometers (nm) in width and may be as long as 14,000nm.[52]
Their life cycle is thought to begin with a virion attaching to specific cell-surface receptors such as C-type lectins, DC-SIGN, or integrins, which is followed by fusion of the viral envelope with cellular membranes.[53] The virions taken up by the cell then travel to acidic endosomes and lysosomes where the viral envelope glycoprotein GP is cleaved.[53] This processing appears to allow the virus to bind to cellular proteins enabling it to fuse with internal cellular membranes and release the viral nucleocapsid.[53] The Ebolavirus structural glycoprotein (known as GP1,2) is responsible for the virus' ability to bind to and infect targeted cells.[54] The viral RNA polymerase, encoded by the L gene, partially uncoats the nucleocapsid and transcribes the genes into positive-strand mRNAs, which are then translated into structural and nonstructural proteins. The most abundant protein produced is the nucleoprotein, whose concentration in the host cell determines when L switches from gene transcription to genome replication. Replication of the viral genome results in full-length, positive-strand antigenomes that are, in turn, transcribed into genome copies of negative-strand virus progeny.[55] Newly synthesised structural proteins and genomes self-assemble and accumulate near the inside of the cell membrane. Virions bud off from the cell, gaining their envelopes from the cellular membrane from which they bud. The mature progeny particles then infect other cells to repeat the cycle. The genetics of the Ebola virus are difficult to study because of EBOV's virulent characteristics.[56]
Transmission
Life cycles of the EbolavirusAn illustration of safe burial practices
It is believed that between people, Ebola disease spreads only by direct contact with the blood or other body fluids of a person who has developed symptoms of the disease.[57][58][59] Body fluids that may contain Ebola viruses include saliva, mucus, vomit, feces, sweat, tears, breast milk, urine and semen.[6][43] The WHO states that only people who are very sick are able to spread Ebola disease in saliva, and the virus has not been reported to be transmitted through sweat. Most people spread the virus through blood, feces and vomit.[60] Entry points for the virus include the nose, mouth, eyes, open wounds, cuts and abrasions.[43] Ebola may be spread through large droplets; however, this is believed to occur only when a person is very sick.[61] This contamination can happen if a person is splashed with droplets.[61] Contact with surfaces or objects contaminated by the virus, particularly needles and syringes, may also transmit the infection.[62][63] The virus is able to survive on objects for a few hours in a dried state, and can survive for a few days within body fluids outside of a person.[43][64]
The Ebola virus may be able to persist for more than three months in the semen after recovery, which could lead to infections via sexual intercourse.[6][65][66] Virus persistence in semen for over a year has been recorded in a national screening programme.[67] Ebola may also occur in the breast milk of women after recovery, and it is not known when it is safe to breastfeed again.[7] The virus was also found in the eye of one patient, in 2014, two months after it was cleared from his blood.[68] Otherwise, people who have recovered are not infectious.[62]
The potential for widespread infections in countries with medical systems capable of observing correct medical isolation procedures is considered low.[69] Usually when someone has symptoms of the disease, they are unable to travel without assistance.[70]
Dead bodies remain infectious; thus, people handling human remains in practices such as traditional burial rituals or more modern processes such as embalming are at risk.[69] Of the cases of Ebola infections in Guinea during the 2014 outbreak, 69% are believed to have been contracted via unprotected (or unsuitably protected) contact with infected corpses during certain Guinean burial rituals.[71][72]
Health-care workers treating people with Ebola are at greatest risk of infection.[62] The risk increases when they do not have appropriate protective clothing such as masks, gowns, gloves and eye protection; do not wear it properly; or handle contaminated clothing incorrectly.[62] This risk is particularly common in parts of Africa where the disease mostly occurs and health systems function poorly.[73] There has been transmission in hospitals in some African countries that reuse hypodermic needles.[74][75] Some health-care centres caring for people with the disease do not have running water.[76] In the United States the spread to two medical workers treating infected patients prompted criticism of inadequate training and procedures.[77]
Human-to-human transmission of EBOV through the air has not been reported to occur during EVD outbreaks,[5] and airborne transmission has only been demonstrated in very strict laboratory conditions, and then only from pigs to primates, but not from primates to primates.[57][63] Spread of EBOV by water, or food other than bushmeat, has not been observed.[62][63] No spread by mosquitos or other insects has been reported.[62] Other possible methods of transmission are being studied.[64]
Airborne transmission among humans is theoretically possible due to the presence of Ebola virus particles in saliva, which can be discharged into the air with a cough or sneeze, but observational data from previous epidemics suggests the actual risk of airborne transmission is low.[78] A number of studies examining airborne transmission broadly concluded that transmission from pigs to primates could happen without direct contact because, unlike humans and primates, pigs with EVD get very high ebolavirus concentrations in their lungs, and not their bloodstream.[79] Therefore, pigs with EVD can spread the disease through droplets in the air or on the ground when they sneeze or cough.[80] By contrast, humans and other primates accumulate the virus throughout their body and specifically in their blood, but not very much in their lungs.[80] It is believed that this is the reason researchers have observed pig to primate transmission without physical contact, but no evidence has been found of primates being infected without actual contact, even in experiments where infected and uninfected primates shared the same air.[79][80]
Initial case
Bushmeat having been smoked in Ghana. In Africa, wild animals including fruit bats are hunted for food and are referred to as bushmeat. In equatorial Africa, human consumption of bushmeat has been linked to animal-to-human transmission of diseases, including Ebola.
Although it is not entirely clear how Ebola initially spreads from animals to humans, the spread is believed to involve direct contact with an infected wild animal or fruit bat.[62] Besides bats, other wild animals that are sometimes infected with EBOV include several species of monkeys such as baboons, great apes (chimpanzees and gorillas), and duikers (a species of antelope).[84]
Animals may become infected when they eat fruit partially eaten by bats carrying the virus.[85] Fruit production, animal behavior and other factors may trigger outbreaks among animal populations.[85]
Evidence indicates that both domestic dogs and pigs can also be infected with EBOV.[86] Dogs do not appear to develop symptoms when they carry the virus, and pigs appear to be able to transmit the virus to at least some primates.[86] Although some dogs in an area in which a human outbreak occurred had antibodies to EBOV, it is unclear whether they played a role in spreading the disease to people.[86]
Bats were known to roost in the cotton factory in which the first cases of the 1976 and 1979 outbreaks were observed, and they have also been implicated in Marburg virus infections in 1975 and 1980.[88] Of 24plant and 19vertebrate species experimentally inoculated with EBOV, only bats became infected.[89] The bats displayed no clinical signs of disease, which is considered evidence that these bats are a reservoir species of EBOV. In a 2002–2003 survey of 1,030animals including 679bats from Gabon and the Republic of the Congo, immunoglobulin G (IgG) immune defense molecules indicative of Ebola infection were found in three bat species; at various periods of study, between 2.2 and 22.6% of bats were found to contain both RNA sequences and IgG molecules indicating Ebola infection.[90] Antibodies against Zaire and Reston viruses have been found in fruit bats in Bangladesh, suggesting that these bats are also potential hosts of the virus and that the filoviruses are present in Asia.[91]
Between 1976 and 1998, in 30,000mammals, birds, reptiles, amphibians and arthropods sampled from regions of EBOV outbreaks, no Ebola virus was detected apart from some genetic traces found in six rodents (belonging to the species Mus setulosus and Praomys) and one shrew (Sylvisorex ollula) collected from the Central African Republic.[88][92] However, further research efforts have not confirmed rodents as a reservoir.[93] Traces of EBOV were detected in the carcasses of gorillas and chimpanzees during outbreaks in 2001 and 2003, which later became the source of human infections. However, the high rates of death in these species resulting from EBOV infection make it unlikely that these species represent a natural reservoir for the virus.[88]
EBOV is thought to infect humans through contact with mucous membranes or skin breaks.[57] After infection, endothelial cells (cells lining the inside of blood vessels), liver cells, and several types of immune cells such as macrophages, monocytes, and dendritic cells are the main targets of attack.[57] Following infection, immune cells carry the virus to nearby lymph nodes where further reproduction of the virus takes place.[57] From there the virus can enter the bloodstream and lymphatic system and spread throughout the body.[57] Macrophages are the first cells infected with the virus, and this infection results in programmed cell death.[52] Other types of white blood cells, such as lymphocytes, also undergo programmed cell death leading to an abnormally low concentration of lymphocytes in the blood.[57] This contributes to the weakened immune response seen in those infected with EBOV.[57]
After infection, a secreted glycoprotein, small soluble glycoprotein (sGP or GP) is synthesised. EBOV replication overwhelms protein synthesis of infected cells and the host immune defences. The GP forms a trimeric complex, which tethers the virus to the endothelial cells. The sGP forms a dimeric protein that interferes with the signalling of neutrophils, another type of white blood cell. This enables the virus to evade the immune system by inhibiting early steps of neutrophil activation.[medical citation needed] Furthermore, the virus is capable of hijacking cellular metabolism. Studies have shown that Ebola virus-like particles can reprogram metabolism in both vascular and immune cells.[98]
The VP24 and VP35 structural proteins of EBOV play a key role in this interference. When a cell is infected with EBOV, receptors located in the cell's cytosol (such as RIG-I and MDA5) or outside of the cytosol (such as Toll-like receptor 3 (TLR3), TLR7, TLR8 and TLR9) recognise infectious molecules associated with the virus.[54] On TLR activation, proteins including interferon regulatory factor 3 and interferon regulatory factor 7 trigger a signalling cascade that leads to the expression of type 1 interferons.[54] The type 1 interferons are then released and bind to the IFNAR1 and IFNAR2 receptors expressed on the surface of a neighbouring cell.[54] Once interferon has bound to its receptors on the neighbouring cell, the signalling proteins STAT1 and STAT2 are activated and move to the cell's nucleus.[54] This triggers the expression of interferon-stimulated genes, which code for proteins with antiviral properties.[54] EBOV's V24 protein blocks the production of these antiviral proteins by preventing the STAT1 signalling protein in the neighbouring cell from entering the nucleus.[54] The VP35 protein directly inhibits the production of interferon-beta.[99] By inhibiting these immune responses, EBOV may quickly spread throughout the body.[52]
Diagnosis
When EVD is suspected, travel, work history, and exposure to wildlife are important factors with respect to further diagnostic efforts.[100]
The specific diagnosis of EVD is confirmed by isolating the virus, detecting its RNA or proteins, or detecting antibodies against the virus in a person's blood.[103] Isolating the virus by cell culture, detecting the viral RNA by polymerase chain reaction (PCR)[8][25] and detecting proteins by enzyme-linked immunosorbent assay (ELISA) are methods best used in the early stages of the disease and also for detecting the virus in human remains.[8][103] Detecting antibodies against the virus is most reliable in the later stages of the disease and in those who recover.[103]IgM antibodies are detectable two days after symptom onset and IgG antibodies can be detected six to 18 days after symptom onset.[25] During an outbreak, isolation of the virus with cell culture methods is often not feasible. In field or mobile hospitals, the most common and sensitive diagnostic methods are real-time PCR and ELISA.[104] In 2014, with new mobile testing facilities deployed in parts of Liberia, test results were obtained 3–5 hours after sample submission.[105] In 2015, a rapid antigen test which gives results in 15 minutes was approved for use by WHO.[106] It is able to confirm Ebola in 92% of those affected and rule it out in 85% of those not affected.[106]
An Ebola vaccine, rVSV-ZEBOV, was approved in the United States in December 2019.[10] It appears to be fully effective ten days after being given.[10] It was studied in Guinea between 2014 and 2016.[10] More than 100,000 people have been vaccinated against Ebola as of 2019[update].[113] The WHO reported that approximately 345,000 people were given the vaccine during the Kivu Ebola epidemic from 2018 to 2020.[114]
Infection control
VHF isolation precautions poster
Community awareness of the benefits on survival chances of admitting cases early is important for the infected and infection control [4]
Caregivers
British woman wearing protective gear
People who care for those infected with Ebola should wear protective clothing including masks, gloves, gowns and goggles.[115] The U.S. Centers for Disease Control (CDC) recommend that the protective gear leaves no skin exposed.[116] These measures are also recommended for those who may handle objects contaminated by an infected person's body fluids.[117] In 2014, the CDC began recommending that medical personnel receive training on the proper suit-up and removal of personal protective equipment (PPE); in addition, a designated person, appropriately trained in biosafety, should be watching each step of these procedures to ensure they are done correctly.[116] In Sierra Leone, the typical training period for the use of such safety equipment lasts approximately 12 days.[118] In 2022 in Uganda, lighter personal protection equipment has become available as well as possibilities to monitor and communicate with patients from windows in the treatment tents until it is necessary to enter if e.g. a patient's oxygen levels drop. [4]
Patients and household members
The infected person should be in barrier-isolation from other people.[115] All equipment, medical waste, patient waste and surfaces that may have come into contact with body fluids need to be disinfected.[117] During the 2014 outbreak, kits were put together to help families treat Ebola disease in their homes, which included protective clothing as well as chlorine powder and other cleaning supplies.[119] Education of caregivers in these techniques, and providing such barrier-separation supplies has been a priority of Doctors Without Borders.[120]
Disinfection
Ebolaviruses can be eliminated with heat (heating for 30 to 60 minutes at 60°C or boiling for five minutes). To disinfect surfaces, some lipid solvents such as some alcohol-based products, detergents, sodium hypochlorite (bleach) or calcium hypochlorite (bleaching powder), and other suitable disinfectants may be used at appropriate concentrations.[84][121]
General population
Education of the general public about the risk factors for Ebola infection and of the protective measures individuals may take to prevent infection is recommended by the World Health Organization.[1] These measures include avoiding direct contact with infected people and regular hand washing using soap and water.[122]
Bushmeat
Bushmeat, an important source of protein in the diet of some Africans, should be handled and prepared with appropriate protective clothing and thoroughly cooked before consumption.[1] Some research suggests that an outbreak of Ebola disease in the wild animals used for consumption may result in a corresponding human outbreak. Since 2003, such animal outbreaks have been monitored to predict and prevent Ebola outbreaks in humans.[123]
Corpses, burial
If a person with Ebola disease dies, direct contact with the body should be avoided.[115] Certain burial rituals, which may have included making various direct contacts with a dead body, require reformulation so that they consistently maintain a proper protective barrier between the dead body and the living.[124][125][126] Social anthropologists may help find alternatives to traditional rules for burials.[127]
Transport, travel, contact
Transportation crews are instructed to follow a certain isolation procedure, should anyone exhibit symptoms resembling EVD.[128]As of August 2014[update], the WHO does not consider travel bans to be useful in decreasing spread of the disease.[70] In October 2014, the CDC defined four risk levels used to determine the level of 21-day monitoring for symptoms and restrictions on public activities.[129] In the United States, the CDC recommends that restrictions on public activity, including travel restrictions, are not required for the following defined risk levels:[129]
having been in a country with widespread Ebola disease transmission and having no known exposure (low risk); or having been in that country more than 21 days ago (no risk)
encounter with a person showing symptoms; but not within three feet of the person with Ebola without wearing PPE; and no direct contact with body fluids
having had brief skin contact with a person showing symptoms of Ebola disease when the person was believed to be not very contagious (low risk)
in countries without widespread Ebola disease transmission: direct contact with a person showing symptoms of the disease while wearing PPE (low risk)
contact with a person with Ebola disease before the person was showing symptoms (no risk).
The CDC recommends monitoring for the symptoms of Ebola disease for those both at "low risk" and at higher risk.[129]
Laboratory
In laboratories where diagnostic testing is carried out, biosafety level 4-equivalent containment is required.[130] Laboratory researchers must be properly trained in BSL-4 practices and wear proper PPE.[130]
Isolation
Isolation refers to separating those who are sick from those who are not. Quarantine refers to separating those who may have been exposed to a disease until they either show signs of the disease or are no longer at risk.[131] Quarantine, also known as enforced isolation, is usually effective in decreasing spread.[132][133] Governments often quarantine areas where the disease is occurring or individuals who may transmit the disease outside of an initial area.[134] In the United States, the law allows quarantine of those infected with ebolaviruses.[135][136]
Contact tracing
Contact tracing is considered important to contain an outbreak. It involves finding everyone who had close contact with infected individuals and monitoring them for signs of illness for 21 days. If any of these contacts comes down with the disease, they should be isolated, tested and treated. Then the process is repeated, tracing the contacts' contacts.[137][138]
In October 2020, the U.S. Food and Drug Administration (FDA) approved atoltivimab/maftivimab/odesivimab with an indication for the treatment of infection caused by Zaire ebolavirus.[13]
Standard support
A hospital isolation ward in Gulu, Uganda, during the October 2000 outbreak
Where hospital care is not possible, the WHO's guidelines for home care have been relatively successful. Recommendations include using towels soaked in a bleach solution when moving infected people or bodies and also applying bleach on stains. It is also recommended that the caregivers wash hands with bleach solutions and cover their mouth and nose with a cloth.[144]
Death, if it occurs, follows typically six to sixteen days after symptoms appear and is often due to low blood pressure from fluid loss.[2] Early supportive care to prevent dehydration may reduce the risk of death.[143]
Post-Ebola virus syndrome
If an infected person survives, recovery may be quick and complete.[25][147] However, a large portion of survivors develop post-Ebola virus syndrome after the acute phase of the infection.[148]
Ebola can stay in some body parts like the eyes,[150] breasts, and testicles after infection.[6][151] Sexual transmission after recovery has been suspected.[152][153] If sexual transmission occurs following recovery it is believed to be a rare event.[154] One case of a condition similar to meningitis has been reported many months after recovery, as of October 2015[update].[155]
Cotton factory in Nzara, South Sudan, where the first outbreak occurred
The first known outbreak of EVD was identified only after the fact. It occurred between June and November 1976, in Nzara, South Sudan[44][156] (then part of Sudan), and was caused by Sudan virus (SUDV). The Sudan outbreak infected 284 people and killed 151. The first identifiable case in Sudan occurred on 27 June in a storekeeper in a cotton factory in Nzara, who was hospitalised on 30 June and died on 6 July.[35][157] Although the WHO medical staff involved in the Sudan outbreak knew that they were dealing with a heretofore unknown disease, the actual "positive identification" process and the naming of the virus did not occur until some months later in Zaire.[157]
A CDC worker incinerates medical waste from Ebola patients in Zaire in 1976.
On 26 August 1976, the second outbreak of EVD began in Yambuku, a small rural village in Mongala District in northern Zaire (now known as the Democratic Republic of the Congo).[158][159] This outbreak was caused by EBOV, formerly designated Zaire ebolavirus, a different member of the genusEbolavirus than in the first Sudan outbreak. The first person infected with the disease was the village school's headmaster Mabalo Lokela, who began displaying symptoms on 26 August 1976.[160] Lokela had returned from a trip to Northern Zaire near the border of the Central African Republic, after visiting the Ebola River between 12 and 22 August. He was originally believed to have malaria and was given quinine. However, his symptoms continued to worsen, and he was admitted to Yambuku Mission Hospital on 5 September. Lokela died on 8 September 14 days after he began displaying symptoms.[161][162]
Soon after Lokela's death, others who had been in contact with him also died, and people in Yambuku began to panic. The country's Minister of Health and Zaire President Mobutu Sese Seko declared the entire region, including Yambuku and the country's capital, Kinshasa, a quarantine zone. No-one was permitted to enter or leave the area, and roads, waterways, and airfields were placed under martial law. Schools, businesses and social organisations were closed.[163] The initial response was led by Congolese doctors, including Jean-Jacques Muyembe-Tamfum, one of the discoverers of Ebola. Muyembe took a blood sample from a Belgian nun; this sample would eventually be used by Peter Piot to identify the previously unknown Ebola virus.[164] Muyembe was also the first scientist to come into direct contact with the disease and survive.[165] Researchers from the Centers for Disease Control and Prevention (CDC), including Piot, co-discoverer of Ebola, later arrived to assess the effects of the outbreak, observing that "the whole region was in panic."[166][167][168]
Piot concluded that Belgian nuns had inadvertently started the epidemic by giving unnecessary vitamin injections to pregnant women without sterilizing the syringes and needles. The outbreak lasted 26 days and the quarantine lasted two weeks. Researchers speculated that the disease disappeared due to the precautions taken by locals, the quarantine of the area, and discontinuing of the injections.[163]
During this outbreak, Ngoy Mushola recorded the first clinical description of EVD in Yambuku, where he wrote the following in his daily log: "The illness is characterised with a high temperature of about 39°C (102°F), haematemesis, diarrhoea with blood, retrosternal abdominal pain, prostration with 'heavy' articulations, and rapid evolution death after a mean of three days."[169]
The virus responsible for the initial outbreak, first thought to be the Marburg virus, was later identified as a new type of virus related to the genus Marburgvirus. Virus strain samples isolated from both outbreaks were named "Ebola virus" after the Ebola River, near the first-identified viral outbreak site in Zaire.[35] Reports conflict about who initially coined the name: either Karl Johnson of the American CDC team[170] or Belgian researchers.[171] Subsequently, a number of other cases were reported, almost all centred on the Yambuku mission hospital or close contacts of another case.[160] In all, 318 cases and 280 deaths (an 88% fatality rate) occurred in Zaire.[172] Although the two outbreaks were at first believed connected, scientists later realised that they were caused by two distinct ebolaviruses, SUDV and EBOV.[159]
In 2000, Uganda had an outbreak infecting 425 and killing 224; in this case, the Sudan virus was found to be the Ebola species responsible for the outbreak.[1]
In 2003, an outbreak in the DRC infected 143 and killed 128, a 90% death rate, the highest of a genusEbolavirus outbreak to date.[173]
In 2004, a Russian scientist died from Ebola after sticking herself with an infected needle.[174]
Between April and August 2007, a fever epidemic[175] in a four-village region[176] of the DRC was confirmed in September to have been cases of Ebola.[177] Many people who attended the recent funeral of a local village chief died.[176] The 2007 outbreak eventually infected 264 individuals and killed 187.[1]
On 30 November 2007, the Uganda Ministry of Health confirmed an outbreak of Ebola in the Bundibugyo District in Western Uganda. After confirming samples tested by the United States National Reference Laboratories and the Centers for Disease Control, the World Health Organization (WHO) confirmed the presence of a new species of genusEbolavirus, which was tentatively named Bundibugyo.[178] The WHO reported 149 cases of this new strain and 37 of those led to deaths.[1]
The WHO confirmed two small outbreaks in Uganda in 2012, both caused by the Sudan variant. The first outbreak affected seven people, killing four, and the second affected 24, killing 17.[1]
On 17 August 2012, the Ministry of Health of the DRC reported an outbreak of the Ebola-Bundibugyo variant[179] in the eastern region.[180][181] Other than its discovery in 2007, this was the only time that this variant has been identified as responsible for an outbreak. The WHO revealed that the virus had sickened 57 people and killed 29. The probable cause of the outbreak was tainted bush meat hunted by local villagers around the towns of Isiro and Viadana.[1][182]
In 2014, an outbreak occurred in the DRC. Genome-sequencing showed that this outbreak was not related to the 2014–15 West Africa Ebola virus outbreak, but was the same EBOV species, the Zaire species.[183] It began in August 2014, and was declared over in November with 66 cases and 49 deaths.[184] This was the 7th outbreak in the DRC, three of which occurred during the period when the country was known as Zaire.[185]
Cases and deaths from April 2014 to July 2015 during the 2013–2015 outbreak
In March 2014, the World Health Organization (WHO) reported a major Ebola outbreak in Guinea, a West African nation.[186] Researchers traced the outbreak to a one-year-old child who died in December 2013.[187][188] The disease rapidly spread to the neighbouring countries of Liberia and Sierra Leone. It was the largest Ebola outbreak ever documented, and the first recorded in the region.[186] On 8 August 2014, the WHO declared the epidemic an international public health emergency. Urging the world to offer aid to the affected regions, its Director-General said, "Countries affected to date simply do not have the capacity to manage an outbreak of this size and complexity on their own. I urge the international community to provide this support on the most urgent basis possible."[189] By mid-August 2014, Doctors Without Borders reported the situation in Liberia's capital, Monrovia, was "catastrophic" and "deteriorating daily". They reported that fears of Ebola among staff members and patients had shut down much of the city's health system, leaving many people without medical treatment for other conditions.[190] In a 26 September statement, WHO said, "The Ebola epidemic ravaging parts of West Africa is the most severe acute public health emergency seen in modern times. Never before in recorded history has a biosafety level four pathogen infected so many people so quickly, over such a broad geographical area, for so long."[191]
Intense contact tracing and strict isolation largely prevented further spread of the disease in the countries that had imported cases.
It caused significant mortality, with a considerable case fatality rate.[192][193][194][note 1] By the end of the epidemic, 28,616 people had been infected; of these, 11,310 had died, for a case-fatality rate of 40%.[195] As of 8May2016[update], 28,646 suspected cases and 11,323 deaths were reported;[15][196] however, the WHO said that these numbers may be underestimated.[197] Because they work closely with the body fluids of infected patients, healthcare workers were especially vulnerable to infection; in August 2014, the WHO reported that 10% of the dead were healthcare workers.[198]
2014 Ebola virus epidemic in West Africa
In September 2014, it was estimated that the countries' capacity for treating Ebola patients was insufficient by the equivalent of 2,122 beds; by December there were a sufficient number of beds to treat and isolate all reported Ebola cases, although the uneven distribution of cases was causing serious shortfalls in some areas.[199] On 28 January 2015, the WHO reported that for the first time since the week ending 29 June 2014, there had been fewer than 100 new confirmed cases reported in a week in the three most-affected countries. The response to the epidemic then moved to a second phase, as the focus shifted from slowing transmission to ending the epidemic.[200] On 8 April 2015, the WHO reported only 30 confirmed cases, the lowest weekly total since the third week of May 2014.[201]
On 29 December 2015, 42 days after the last person tested negative for a second time, Guinea was declared free of Ebola transmission.[202] At that time, a 90-day period of heightened surveillance was announced by that agency. "This is the first time that all three countries – Guinea, Liberia and Sierra Leone – have stopped the original chains of transmission ...", the organisation stated in a news release.[203] A new case was detected in Sierra Leone on 14 January 2016.[204] However, the outbreak was declared no longer an emergency on 29 March 2016.[18]
On 19 September, Eric Duncan flew from his native Liberia to Texas; five days later he began showing symptoms and visited a hospital but was sent home. His condition worsened and he returned to the hospital on 28 September, where he died on 8 October. Health officials confirmed a diagnosis of Ebola on 30 September – the first case in the United States.[205]
In early October, Teresa Romero, a 44-year-old Spanish nurse, contracted Ebola after caring for a priest who had been repatriated from West Africa. This was the first transmission of the virus to occur outside Africa.[206] Romero tested negative for the disease on 20 October, suggesting that she may have recovered from Ebola infection.[207]
On 12 October, the Centers for Disease Control and Prevention (CDC) confirmed that a nurse in Texas, Nina Pham, who had treated Duncan tested positive for the Ebola virus, the first known case of transmission in the United States.[208] On 15 October, a second Texas health-care worker who had treated Duncan was confirmed to have the virus.[77][209] Both of these people recovered.[210] An unrelated case involved a doctor in New York City, who returned to the United States from Guinea after working with Médecins Sans Frontières and tested positive for Ebola on 23 October.[211] The person recovered and was discharged from Bellevue Hospital on 11 November.[210] On 24 December 2014, a laboratory in Atlanta, Georgia reported that a technician had been exposed to Ebola.[212]
On 11 May 2017, the DRC Ministry of Public Health notified the WHO about an outbreak of Ebola. Four people died, and four people survived; five of these eight cases were laboratory-confirmed. A total of 583 contacts were monitored. On 2 July 2017, the WHO declared the end of the outbreak.[215]
On 14 May 2018, the World Health Organization reported that "the Democratic Republic of Congo reported 39 suspected, probable or confirmed cases of Ebola between 4 April and 13 May, including 19 deaths."[216] Some 393 people identified as contacts of Ebola patients were being followed up. The outbreak centred on the Bikoro, Iboko, and Wangata areas in Equateur province,[216] including in the large city of Mbandaka. The DRC Ministry of Public Health approved the use of an experimental vaccine.[217][218][219] On 13 May 2018, WHO Director-General Tedros Adhanom Ghebreyesus visited Bikoro.[220] Reports emerged that maps of the area were inaccurate, not so much hampering medical providers as epidemiologists and officials trying to assess the outbreak and containment efforts.[221] The 2018 outbreak in the DRC was declared over on 24 July 2018.[22]
On 1 August 2018, the world's 10th Ebola outbreak was declared in North Kivu province of the Democratic Republic of the Congo. It was the first Ebola outbreak in a military conflict zone, with thousands of refugees in the area.[222][223] By November 2018, nearly 200 Congolese had died of Ebola, about half of them from the city of Beni, where armed groups are fighting over the region's mineral wealth, impeding medical relief efforts.[224]
By March 2019, this became the second largest Ebola outbreak ever recorded, with more than 1,000 cases and insecurity continuing to be the major resistance to providing an adequate response.[225][226]As of 4June2019[update], the WHO reported 2025 confirmed and probable cases with 1357 deaths.[227] In June 2019, two people died of Ebola in neighbouring Uganda.[228]
In July 2019, an infected man travelled to Goma, home to more than two million people.[229] One week later, on 17 July 2019, the WHO declared the Ebola outbreak a global health emergency, the fifth time such a declaration has been made by the organisation.[230] A government spokesman said that half of the Ebola cases are unidentified, and he added that the current outbreak could last up to three years.[231]
On 25 June 2020, the second biggest EVD outbreak ever was declared over.[232]
2020 Équateur province
On 1 June 2020, the Congolese health ministry announced a new DRC outbreak of Ebola in Mbandaka, Équateur Province, a region along the Congo River. Genome sequencing suggests that this outbreak, the 11th outbreak since the virus was first discovered in the country in 1976, is unrelated to the one in North Kivu Province or the previous outbreak in the same area in 2018. It was reported that six cases had been identified; four of the people had died. It is expected that more people will be identified as surveillance activities increase.[233] By 15 June the case count had increased to 17 with 11 deaths, with more than 2,500 people having been vaccinated.[234] The 11th EVD outbreak was officially declared over on 19 November 2020.[235] By the time the Équateur outbreak ended, it had 130 confirmed cases with 75 recoveries and 55 deaths.
2021
North Kivu
On 7 February 2021, the Congolese health ministry announced a new case of Ebola near Butembo, North Kivu detected a day before. The case was a 42-year-old woman who had symptoms of Ebola in Biena on 1 February 2021. A few days after, she died in a hospital in Butembo. The WHO said that more than 70 people with contact with the woman had been tracked.[236][237]
On 11 February 2021, another woman who had contact with the previous woman died in the same town, and the number of traced contacts increased to 100.[238] A day after, a third case was detected in Butembo.[239]
On 3 May 2021, the 12th EVD outbreak was declared over, resulting in 12 cases and six deaths.[240][241] Heightened surveillance will continue for 90 days after the declaration, in case of resurgence.[240]
Guinea
In February 2021, Sakoba Keita, head of Guinea's national health agency confirmed that three people had died of Ebola in the south-eastern region near the city of Nzérékoré. A further five people also tested positive. Keita also confirmed more testing was underway, and attempts to trace and isolate further cases had begun.[242] On 14 February, the Guinean government declared an Ebola epidemic.[243] The outbreak may have started following reactivation of a latent case in a survivor of an earlier outbreak.[244][245] As of 4 May 2021, 23 cases were reported, with no new cases or deaths since 3 April 2021.[240] A 42-day countdown period was started on 8 May 2021, and on 19 June, the outbreak was declared over.[240][246]
Ivory Coast
On 14 August 2021, The Ministry of Health of Cote d’Ivoire confirmed the country's first case of Ebola since 1994. This came after the Institut Pasteur in Cote d'Ivoire confirmed the Ebola Virus Disease in samples collected from a patient, who was hospitalized in the commercial capital of Abidjan, after arriving from Guinea.[247]
However, on 31 August 2021, the WHO found that, after further tests in a laboratory in Lyon, the patient did not have Ebola. The cause of her disease is still being analyzed.[248]
2022
On 23 April 2022, a case of Ebola was confirmed in the DRC in the Equateur province. The case was a 31-year-old man whose symptoms began on 5 April, but did not seek treatment for over a week. On 21 April, he was admitted to an Ebola treatment centre and died later that day.[249] By 24 May 2022, there were 5 recorded deaths in the DRC.[250] On 15 August, the fifth case was buried, and the outbreak was declared over, 42 days after, on 4 July 2022.[251]
In September 2022, Uganda reported 7 cases infected with the Ebola Sudan strain,[252] but by mid-October the count had increased to 63.[253] In November 2022, the outbreak in Uganda continued - still without a vaccine.[4] On 10 January 2023, the outbreak was considered over after no new cases had been reported for 42 days; the outbreak killed nearly 80 people.[254]
Ebolavirus is classified as a biosafety level 4 agent, as well as a Category A bioterrorism agent by the Centers for Disease Control and Prevention.[96][255] It has the potential to be weaponised for use in biological warfare,[256][257] and was investigated by Biopreparat for such use, but might be difficult to prepare as a weapon of mass destruction because the virus becomes ineffective quickly in open air.[258] Fake emails pretending to be Ebola information from the WHO or the Mexican government have, in 2014, been misused to spread computer malware.[259] The BBC reported in 2015 that "North Korean state media has suggested the disease was created by the U.S. military as a biological weapon."[260]
William Close's 1995 Ebola: A Documentary Novel of Its First Explosion[264][265] and 2002 Ebola: Through the Eyes of the People focused on individuals' reactions to the 1976 Ebola outbreak in Zaire.[266][267]
As the Ebola virus epidemic in West Africa developed in 2014, a number of popular self-published and well-reviewed books containing sensational and misleading information about the disease appeared in electronic and printed formats. The authors of some such books admitted that they lacked medical credentials and were not technically qualified to give medical advice. The World Health Organization and the United Nations stated that such misinformation had contributed to the spread of the disease.[270]
Other animals
Wild animals
Ebola has a high mortality rate among primates.[271] Frequent outbreaks of Ebola may have resulted in the deaths of 5,000 gorillas.[272] Outbreaks of Ebola may have been responsible for an 88% decline in tracking indices of observed chimpanzee populations in the 420km2 Lossi Sanctuary between 2002 and 2003.[273] Transmission among chimpanzees through meat consumption constitutes a significant risk factor, whereas contact between the animals, such as touching dead bodies and grooming, is not.[274]
Recovered gorilla carcasses have contained multiple Ebola virus strains, suggesting multiple introductions of the virus. Bodies decompose quickly and carcasses are not infectious after three to four days. Contact between gorilla groups is rare, suggesting that transmission among gorilla groups is unlikely, and that outbreaks result from transmission between viral reservoirs and animal populations.[273]
Domestic animals
In 2012, it was demonstrated that the virus can travel without contact from pigs to nonhuman primates, although the same study failed to achieve transmission in that manner between primates.[86][275]
Dogs may become infected with EBOV but not develop symptoms. Dogs in some parts of Africa scavenge for food, and they sometimes eat EBOV-infected animals and also the corpses of humans. A 2005 survey of dogs during an EBOV outbreak found that although they remain asymptomatic, about 32 percent of dogs closest to an outbreak showed a seroprevalence for EBOV versus nine percent of those farther away.[276] The authors concluded that there were "potential implications for preventing and controlling human outbreaks."
Reston virus
For more about the outbreak in Virginia, US, see Reston virus.
In late 1989, Hazelton Research Products' Reston Quarantine Unit in Reston, Virginia, had an outbreak of fatal illness amongst certain lab monkeys. This lab outbreak was initially diagnosed as simian haemorrhagic fever virus (SHFV) and occurred amongst a shipment of crab-eating macaque monkeys imported from the Philippines. Hazelton's veterinary pathologist in Reston sent tissue samples from dead animals to the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Maryland, where an ELISA test indicated the antibodies present in the tissue were a response to Ebola virus and not SHFV.[277] An electron microscopist from USAMRIID discovered filoviruses similar in appearance, in crystalloid aggregates and as single filaments with a shepherd's hook, to Ebola in the tissue samples sent from Hazelton Research Products' Reston Quarantine Unit.[278]
A US Army team headquartered at USAMRIID euthanised the surviving monkeys, and brought all the dead monkeys to Fort Detrick for study by the Army's veterinary pathologists and virologists, and eventual disposal under safe conditions.[277] Blood samples were taken from 178 animal handlers during the incident.[279] Of those, six animal handlers eventually seroconverted, including one who had cut himself with a bloody scalpel.[97][280] Despite its status as a Level‑4 organism and its apparent pathogenicity in monkeys, when the handlers did not become ill, the CDC concluded that the virus had a very low pathogenicity to humans.[280][281]
The Philippines and the United States had no previous cases of Ebola infection, and upon further isolation, researchers concluded it was another strain of Ebola, or a new filovirus of Asian origin, which they named Reston ebolavirus (RESTV) after the location of the incident.[277] Reston virus (RESTV) can be transmitted to pigs.[86] Since the initial outbreak it has since been found in nonhuman primates in Pennsylvania, Texas, and Italy,[282] where the virus had infected pigs.[283] According to the WHO, routine cleaning and disinfection of pig (or monkey) farms with sodium hypochlorite or detergents should be effective in inactivating the Reston ebolavirus. Pigs that have been infected with RESTV tend to show symptoms of the disease.[284]
Researchers looking at slides of cultures of cells that make monoclonal antibodies. These are grown in a lab and the researchers are analyzing the products to select the most promising.
As of July2015[update], no medication has been proven safe and effective for treating Ebola. By the time the Ebola virus epidemic in West Africa began in 2013, there were at least nine different candidate treatments. Several trials were conducted in late 2014, and early 2015, but some were abandoned due to lack of efficacy or lack of people to study.[285]
The diagnostic tests currently available require specialised equipment and highly trained personnel. Since there are few suitable testing centres in West Africa, this leads to delay in diagnosis.[289]
On 29 November 2014, a new 15-minute Ebola test was reported that if successful, "not only gives patients a better chance of survival, but it prevents transmission of the virus to other people." The new equipment, about the size of a laptop and solar-powered, allows testing to be done in remote areas.[290]
Animal models and in particular non-human primates are being used to study different aspects of Ebola virus disease. Developments in organ-on-a-chip technology have led to a chip-based model for Ebola haemorrhagic syndrome.[292]
↑ The mortality (number of dead per number of healthy per time frame) recorded in Liberia up to 26 August 2014 was 70%.[194] However, due to the estimation method used, the estimated case fatality rate (70.8%) for this particular epidemic differs from the actual ratio between the number of deaths and the number of cases.
Related Research Articles
Marburg virus disease (MVD), formerly Marburg hemorrhagic fever (MHF) is a viral hemorrhagic fever in human and non-human primates caused by either of the two Marburgviruses: Marburg virus (MARV) and Ravn virus (RAVV). Its clinical symptoms are very similar to those of Ebola virus disease (EVD).
Mpox is an infectious viral disease that can occur in humans and other animals. Symptoms include a rash that forms blisters and then crusts over, fever, and swollen lymph nodes. The illness is usually mild, and most infected individuals recover within a few weeks without treatment. The time from exposure to the onset of symptoms ranges from three to seventeen days, and symptoms typically last from two to four weeks. However, cases may be severe, especially in children, pregnant women, or people with suppressed immune systems.
The genus Ebolavirus is a virological taxon included in the family Filoviridae, order Mononegavirales. The members of this genus are called ebolaviruses, and encode their genome in the form of single-stranded negative-sense RNA. The six known virus species are named for the region where each was originally identified: Bundibugyo ebolavirus, Reston ebolavirus, Sudan ebolavirus, Taï Forest ebolavirus, Zaire ebolavirus, and Bombali ebolavirus. The last is the most recent species to be named and was isolated from Angolan free-tailed bats in Sierra Leone. Each species of the genus Ebolavirus has one member virus, and four of these cause Ebola virus disease (EVD) in humans, a type of hemorrhagic fever having a very high case fatality rate. The Reston virus has caused EVD in other primates. Zaire ebolavirus has the highest mortality rate of the ebolaviruses and is responsible for the largest number of outbreaks of the six known species of the genus, including the 1976 Zaire outbreak and the outbreak with the most deaths (2014).
The species Bundibugyo ebolavirus is the taxonomic home of one virus, Bundibugyo virus (BDBV), that forms filamentous virions and is closely related to the infamous Ebola virus (EBOV). The virus causes severe disease in humans in the form of viral hemorrhagic fever and is a Select agent, World Health Organization Risk Group 4 Pathogen, National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogen, Centers for Disease Control and Prevention Category A Bioterrorism Agent, and is listed as a Biological Agent for Export Control by the Australia Group.
The species Taï Forest ebolavirus is a virological taxon included in the genus Ebolavirus, family Filoviridae, order Mononegavirales. The species has a single virus member, Taï Forest virus (TAFV). The members of the species are called Taï Forest ebolaviruses.
The species Sudan ebolavirus is a virological taxon included in the genus Ebolavirus, family Filoviridae, order Mononegavirales. The species has a single virus member, Sudan virus (SUDV). The members of the species are called Sudan ebolaviruses. It was discovered in 1977 and causes Ebola clinically indistinguishable from the ebola Zaire strain, but is less transmissible than it. Unlike with ebola Zaire there is no vaccine available.
Reston virus (RESTV) is one of six known viruses within the genus Ebolavirus. Reston virus causes Ebola virus disease in non-human primates; out of all 6 ebolaviruses, it is one of the only two not known to cause disease in humans, but has caused asymptomatic infections. Reston virus was first described in 1990 as a new "strain" of Ebola virus (EBOV). It is the single member of the species Reston ebolavirus, which is included into the genus Ebolavirus, family Filoviridae, order Mononegavirales. Reston virus is named after Reston, Virginia, US, where the virus was first discovered.
Zaire ebolavirus, more commonly known as Ebola virus, is one of six known species within the genus Ebolavirus. Four of the six known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and other mammals, known as Ebola virus disease (EVD). Ebola virus has caused the majority of human deaths from EVD, and was the cause of the 2013–2016 epidemic in western Africa, which resulted in at least 28,646 suspected cases and 11,323 confirmed deaths.
The 2013–2016 epidemic of Ebola virus disease, centered in West Africa, was the most widespread outbreak of the disease in history. It caused major loss of life and socioeconomic disruption in the region, mainly in Guinea, Liberia and Sierra Leone. The first cases were recorded in Guinea in December 2013; the disease spread to neighbouring Liberia and Sierra Leone, with minor outbreaks occurring in Nigeria and Mali. Secondary infections of medical workers occurred in the United States and Spain. Isolated cases were recorded in Senegal, the United Kingdom and Italy. The number of cases peaked in October 2014 and then began to decline gradually, following the commitment of substantial international resources.
ZMapp is an experimental biopharmaceutical medication comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease. Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, a research scientist at the NML and underwent further development under license by Mapp Biopharmaceutical. ZMapp was first used on humans during the Western African Ebola virus epidemic, having only been previously tested on animals and not yet subjected to a randomized controlled trial. The National Institutes of Health (NIH) ran a clinical trial starting in January 2015 with subjects from Sierra Leone, Guinea, and Liberia aiming to enroll 200 people, but the epidemic waned and the trial closed early, leaving it too statistically underpowered to give a meaningful result about whether ZMapp worked.
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include headache, fatigue, and muscle pain.
In 2014, an outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC) occurred. Genome sequencing has shown that this outbreak was not related to the 2014–15 West Africa Ebola virus epidemic, but was of the same EBOV species. It began in August 2014 and was declared over in November of that year, after 42 days without any new cases. This is the 7th outbreak there, three of which occurred during the period of Zaire.
Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates against lethal infection.
There is a cure for the Ebola virus disease that is currently approved for market the US government has inventory in the Strategic National Stockpile. For past and current Ebola epidemics, treatment has been primarily supportive in nature.
The 2018 Équateur province Ebola outbreak occurred in the north-west of the Democratic Republic of the Congo (DRC) from May to July 2018. It was contained entirely within Équateur province, and was the first time that vaccination with the rVSV-ZEBOV Ebola vaccine had been attempted in the early stages of an Ebola outbreak, with a total of 3,481 people vaccinated. It was the ninth recorded Ebola outbreak in the DRC.
The Kivu Ebola epidemic was an outbreak of Ebola virus disease (EVD) mainly in eastern Democratic Republic of the Congo (DRC), and in other parts of Central Africa, from 2018 to 2020. Between 1 August 2018 and 25 June 2020 it resulted in 3,470 reported cases. The Kivu outbreak also affected Ituri Province, whose first case was confirmed on 13 August 2018. In November 2018, the outbreak became the biggest Ebola outbreak in the DRC's history, and had become the second-largest Ebola outbreak in recorded history worldwide, behind only the 2013–2016 Western Africa epidemic. In June 2019, the virus reached Uganda, having infected a 5-year-old Congolese boy who entered Uganda with his family, but was contained.
In August–November 1976, an outbreak of Ebola virus disease occurred in Zaire. The first recorded case was from Yambuku, a small village in Mongala District, 1,098 kilometres (682 mi) northeast of the capital city of Kinshasa.
On 7 February 2021, the Congolese health ministry announced that a new case of Ebola near Butembo, North Kivu had been detected the previous day. The case was a 42-year-old woman who had symptoms of Ebola in Biena on 1 February 2021. A few days after, she died in a hospital in Butembo. The WHO said that more than 70 people who had contact with the woman had been tracked.
The 2022–2023 Uganda Ebola outbreak was an outbreak of the Sudan ebolavirus, which causes Ebola, from 20 September 2022 until 10 January 2023 in the Western and Central Regions of Uganda. Over 160 people were infected, including 77 people who died. It was Uganda's fifth outbreak with Sudan ebolavirus. The Ugandan Ministry of Health declared the outbreak on 20 September 2022. As of 25 October 2022, there were confirmed cases in the Mubende, Kyegegwa, Kassanda, Kagadi, Bunyanga, Kampala and Wakiso districts. As of 24 October 2022, there were a total of 90 confirmed or probable cases and 44 deaths. On 12 October, the first recorded death in the capital of Kampala occurred; 12 days later on 24 October, there had been a total of 14 infections in the capital in the last two days. On 11 January 2023 after 42 days without new cases the outbreak was declared over.
1 2 "Ebola Treatment Research". NIH: National Institute of Allergy and Infectious Diseases. Archived from the original on 20 August 2019. Retrieved 20 August 2019.
1 2 3 Hoenen T, Groseth A, Falzarano D, Feldmann H (May 2006). "Ebola virus: unravelling pathogenesis to combat a deadly disease". Trends in Molecular Medicine. 12 (5): 206–215. doi:10.1016/j.molmed.2006.03.006. PMID16616875.
↑ Brown CS, Mepham S, Shorten RJ (June 2017). "Ebola Virus Disease: An Update on Epidemiology, Symptoms, Laboratory Findings, Diagnostic Issues, and Infection Prevention and Control Issues for Laboratory Professionals". Clinical Laboratory Medicine (Review). 37 (2): 269–284. doi:10.1016/j.cll.2017.01.003. PMID28457350.
↑ Simpson DI (1977). Marburg and Ebola virus infections: a guide for their diagnosis, management, and control. World Health Organization. p.10f. hdl:10665/37138. ISBN924170036X. WHO offset publication; no. 36.
↑ West TE, von Saint André-von Arnim A (November 2014). "Clinical presentation and management of severe Ebola virus disease". Annals of the American Thoracic Society (Review). 11 (9): 1341–1350. doi:10.1513/AnnalsATS.201410-481PS. PMID25369317.
↑ Pringle CR (2005). "Order Mononegavirales". In Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (eds.). Virus Taxonomy – Eighth Report of the International Committee on Taxonomy of Viruses. San Diego: Elsevier/Academic Press. pp.609–614. ISBN978-0-12-370200-5.
↑ Feldmann H, Geisbert TW, Jahrling PB, Klenk H, Netesov SV, Peters CJ, Sanchez A, Swanepoel R, Volchkov VE (2005). Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (eds.). Virus Taxonomy – Eighth Report of the International Committee on Taxonomy of Viruses. Elsevier/Academic Press. ISBN978-0123702005.
1 2 Gonzalez JP, Pourrut X, Leroy E (2007). "Ebolavirus and Other Filoviruses". Wildlife and Emerging Zoonotic Diseases: The Biology, Circumstances and Consequences of Cross-Species Transmission. Ebolavirus and other filoviruses. Vol.315. pp.363–387. doi:10.1007/978-3-540-70962-6_15. ISBN978-3540709619. PMC7121322. PMID17848072.{{cite book}}: |work= ignored (help)
↑ Morvan JM, Deubel V, Gounon P, Nakouné E, Barrière P, Murri S, etal. (December 1999). "Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic". Microbes and Infection. 1 (14): 1193–1201. doi:10.1016/S1286-4579(99)00242-7. PMID10580275.
1 2 Grolla A, Lucht A, Dick D, Strong JE, Feldmann H (September 2005). "Laboratory diagnosis of Ebola and Marburg hemorrhagic fever". Bull Soc Pathol Exot. 98 (3): 205–09. PMID16267962.
↑ "Viral Hemorrhagic Fever". S.F. Dept Public Health – Infectious Disease Emergencies. July 2008. Archived from the original(PDF) on 20 April 2013. Retrieved 17 August 2014.
↑ Gear JH, Ryan J, Rossouw E (February 1978). "A consideration of the diagnosis of dangerous infectious fevers in South Africa". South African Medical Journal. 53 (7): 235–37. PMID565951.
↑ Bogomolov BP (1998). "Differential diagnosis of infectious diseases with hemorrhagic syndrome". Terapevticheskii Arkhiv. 70 (4): 63–68. PMID9612907.
↑ Organization, World Health (August 2014). "Interim infection prevention and control guidance for care of patients with suspected or confirmed filovirus haemorrhagic fever in health-care settings, with focus on Ebola". WHO Technical Documents. World Health Organization (WHO). hdl:10665/130596. WHO/HIS/SDS/2014.4 Rev. 1.
↑ King JW (2 April 2008). "Ebola Virus". eMedicine. WebMD. Archived from the original on 28 September 2008. Retrieved 6 October 2008.
↑ Formenty P, Libama F, Epelboin A, Allarangar Y, Leroy E, Moudzeo H, etal. (2003). "[Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?]". Med Trop (Mars) (in French). 63 (3): 291–295. PMID14579469.
↑ Ebola response roadmap situation report(PDF) (Report). WHO. 31 December 2014. Archived from the original(PDF) on 31 December 2014. Retrieved 1 January 2015. The reported case fatality rate in the three intense-transmission countries among all cases for whom a definitive outcome is known is 71%.
↑ Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, etal. (May 2002). "Hemorrhagic fever viruses as biological weapons: medical and public health management". Journal of the American Medical Association. 287 (18): 2391–405. doi:10.1001/jama.287.18.2391. PMID11988060.
↑ Grove R (2 June 2006). "More about the people than the virus". Review of Close, William T., Ebola: A Documentary Novel of Its First Explosion. Archived from the original on 21 October 2014. Retrieved 17 September 2014.
↑ Pink B (24 June 2008). "A fascinating perspective". Review of Close, William T., Ebola: Through the Eyes of the People. Archived from the original on 21 October 2014. Retrieved 17 September 2014.
Klenk HD (January 1999). Marburg and Ebola Viruses. Current Topics in Microbiology and Immunology 235. Berlin: Springer-Verlag Telos. ISBN978-3540647294.
Ryabchikova EI, Price BB (2004). Ebola and Marburg Viruses: A View of Infection Using Electron Microscopy. Columbus, Ohio: Battelle Press. ISBN978-1574771312.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
